Santander X Global Challenge
Reimagine Silver Age · 2025
In clinical development
Elevvo is developing a new treatment for early-stage Alzheimer’s disease, based on patent-pending closed-loop auditory stimulation technology that enhances slow-wave activity during sleep.
Clinical programme
In collaboration with
Phase 2a · Nana-Lab
Randomised, cross-over, double-blind, placebo-controlled trial in 37 patients with early-stage Alzheimer’s disease and an amnestic phenotype. Elevvo significantly increased slow-wave amplitude and was associated with improved declarative memory versus placebo.
Declarative memory
Mean word-pair retention. Significant difference versus placebo, p = 0.04.
Mechanism
Median slow-wave amplitude on the stimulation night versus the placebo night. Significant difference versus placebo, p < 10⁻⁶.
Full results of the Nana-Lab trial
Read the preprint on medRxiv →In the media
“Pink noise played during sleep shows promise for Alzheimer’s memory loss”
Recognition
Reimagine Silver Age · 2025
IDEA Futuro category · 2026
Professional contact
For investors and clinical research centres.
Patient contact
Write to us and we will get in touch when we have new clinical trials.